资源描述：
《Download-AccessPharmaceuticalsInc：-访问制药公司》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、CompanyPresentationMarch7,2012CowenandCompany32ndAnnualHealthCareConferenceThispresentationcontainscertainstatementsthatmaybeforward-lookingwithinthemeaningofSection27aoftheSecuritiesActof1933,asamended,includingstatementsrelatingtotheproductportfolioandpipeli
2、neandclinicalprogramsofthecombinedcompany,themarketopportunitiesforMuGard™,thesalesof,marketopportunitiesforandplannedstudiesofProLindac™,themarketopportunitiesforThiarabineandtheCobalaminprograms,andthecombinedcompany’sgoalsandobjectives.Thesestatementsaresub
3、jecttonumerousrisksanduncertainties,includingbutnotlimitedtotherisksdetailedinAccess'sAnnualReportonForm10fortheyearendedDecember31,2010,andotherreportsfiledbythecompanieswiththeSecuritiesandExchangeCommission.Thesematerialsarenotanoffertosellsecuritiesandaren
4、otsolicitinganoffertobuysecurities.1SafeHarborStatement2AboutAccessPharmaceuticalsAccessPharmaceuticalsisanemergingbiopharmaceuticalcompanyfocusedonthetreatmentofcancerandcancersupportivecare.TheCompanycurrentlyhasonemarketedproductandtwoproductsinPhaseIIclini
5、caltrials.ApprovedproductaddressingalargeunmetmedicalneedMuGardisapatientfriendlytreatmentfororalmucositisaddressinga$1.0billionplusmarketTwoPhase2oncologyassetsProprietarycompounds,ProLindacandThiarabine,areinPhase2clinicaltrialsandtargetmulti-billiondollarca
6、ncermarkets,includingmetastaticcolorectalandovarianAttractiveproprietarydrugdeliveryplatformsCobOralandCobaCyte,twodrugdeliveryplatformsbaseduponVitaminB-12absorption,createmultipleproductopportunitiesandprovidediversificationofriskActivepartneringstrategiesMu
7、ltiplepre-licensingpartnerships/collaborationswithpharmacompaniesvalidatedrugdeliverytechnologyplatformsanddevelopmentpipelinePhase2programswillbeout-licensedpriortopivotaltrialsDrugdeliveryprogramslikelytobeout-licensedpriortohumantrialsExperiencedmanagementt
8、eamwithdeepindustryexpertiseandsignificantownershipstake3InvestmentHighlights4ProductPipelineOncologyPipelinePre-clinicalINDPhase1Phase2Phase3ProductPotentialMuGard™FDAApproved>$1B
